The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 12, 2024
Filed:
Jul. 07, 2023
Inserm (Institut National DE LA Sante ET DE LA Recherche Medicale), Paris, FR;
Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;
Universite Claude Bernard—lyon 1, Villeurbanne, FR;
Centre Leon Berard, Lyons, FR;
Kist (Korea Institute of Science and Technology), Seoul, KR;
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris, FR;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, Paris, FR;
UNIVERSITE CLAUDÉBERNARD—LYON 1, Lyons, FR;
CENTRE LEON BERARD, Lyons, FR;
KIST (KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY), Seoul, KI;
Abstract
The present invention relates to a non invasive diagnostic method of pancreatic ductal adenocarcinoma (PDAC) in a subject said method comprising the step of measuring the level of βig-h3 protein in a blood sample wherein the serum level of βig-h3 is positively correlated with the risk of having a PDAC. By following studies on 2 distinct cohorts of 20 and 104 of PDAC patients, and on PDAC mouse model, the inventors show that βig-h3 can be directly detected in the blood sample and βig-h3 is expressed very early in tumorigenesis in pancreatic neoplastic lesions. The present invention also relates to antagonist of βig-h3 protein, for use in the treatment of PDAC. The inventors found that βig-h3 bind directly on CD8T cells by reducing their activation and cytotoxic properties. Furthermore, the use of neutralizing βig-h3 antibodies in PDAC mouse model, reduced tumor growth by enhancing CD8T cell anti-tumoral response. Thus, neutralizing βig-h3 which acts as a novel immunological check-point target in PDAC therefore allows to restore beneficial anti-tumor immunity in PDAC.